Detailed data from Phase 3 ECHELON-3 study demonstrate investigational ADCETRIS regimen reduced risk of death by 37 percent compared to chemotherapy alone
Outlook 2024 remains flat CER sales growth and CORE EBITDA margin of high 20s
Syngene International has reported total income of Rs. 933 crores during the period ended March 31, 2024
IgAN is a heterogeneous, progressive, rare kidney disease and is a major cause of chronic kidney disease worldwide
Morepen Laboratories has reported total income of Rs. 448.62 crores during the period ended December 31, 2023
Revenue from Operations stood at Rs. 2,607 crore, 25% YoY growth. Domestic revenue at Rs. 2,400 crore, 20% YoY growth and export revenue at Rs. 207 crore, 118% YoY growth
The company disclosed that several employees of a subsidiary had their business email addresses stolen
European operations' revenue grew 58.4% to Rs 599.7 crore
Q2FY24 EBITDA up by 105% y-o-y at Rs. 28 crore
Subscribe To Our Newsletter & Stay Updated
